Showing 1 - 10 of 71
The Cardiac Insufficiency Bisoprolol Study (CIBIS) demonstrates that, for patients with heart failure of different aetiologies, administration of the beta1-adrenoceptor blocker bisoprolol as an adjuvant to the standard therapy leads to a significant avoidance of hospital admissions. A...
Persistent link: https://www.econbiz.de/10005590513
Background: In the Ramipril Efficacy In Nephropathy (REIN) trial, ramipril significantly lowered the rate of reaching the combined end-point of doubling of baseline serum creatinine levels or end-stage renal failure (ESRF). Objective: To determine the additional cost per patient-year of chronic...
Persistent link: https://www.econbiz.de/10005590520
Objective: Data from the Acute Infarction Ramipril Efficacy (AIRE) study were used in a cost-effectiveness analysis to determine the incremental cost per life-year gained (LYG) when the ACE inhibitor ramipril was added to conventional treatment in patients with heart failure after acute...
Persistent link: https://www.econbiz.de/10005449120
Alcoholism places a considerable economic burden on society. The rate of relapse of previously weaned alcoholics has been shown to decrease following treatment with acamprosate. Therefore, this study investigated the cost effectiveness of acamprosate in the treatment of alcoholism in Germany...
Persistent link: https://www.econbiz.de/10005404846
Objective: To estimate, from the hospital perspective in Germany, the cost effectiveness of the low-molecular-weight heparin (LMWH) subcutaneous enoxaparin sodium 40mg once daily (ENOX) relative to no pharmacological prophylaxis (NPP) and relative to subcutaneous unfractionated heparin (UFH)...
Persistent link: https://www.econbiz.de/10004990355
Persistent link: https://www.econbiz.de/10004146397
Persistent link: https://www.econbiz.de/10004800631
Persistent link: https://www.econbiz.de/10013456290